Discovery
Pre-clinical
Phase 1
Phase 2

In discovery phase.

Overview

Sym029 is one of our antibody-based approaches for mobilizing and enhancing the activity of the dendritic cells. Currently, we are advancing projects against FLT3 (Sym027), AXL (Sym028) and CD40 with non-overlapping and differentiated mechanisms, which we believe have great potential for use in combination regimens. The majority of tumors have no or very low existing cancer immunity due to a disruption in the cancer immunity cycle. Such tumors can hide from the immune system and are able to grow and develop without the immune system ever recognizing it. Dendritic cells are “experts” in taking up tumor antigens and presenting them to the T-cells and hence a key but under-researched cell type for mounting an anti-tumor¬†immune response.

Target
CD40